List view / Grid view
A PricewaterhouseCoopers report has highlighted the directions that the growth of the contract development and manufacturing organisation (CDMO) outsourcing market will take in the near future.
The CDMO AMRI has said it will boost its production of the malaria drug hydroxychloroquine sulfate, identified as a potential COVID-19 treatment, following an emergency use authorisation from the FDA.
A Contract Development and Manufacturing Organisation (CDMO) has been recognised in six different categories at the 2020 CMO Leadership Awards.
A letter from the CEO of Gilead reveals how the company plans to scale up production of remdesivir in light of the COVID-19 pandemic.
With concerns rising about medicine availability during the global COVID-19 coronavirus pandemic, European Pharmaceutical Review explores how the pharmaceutical supply chain is faring.
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
A change to the law will soon be impacting compounding of certain products beginning on 23 March 2020 the US Food and Drug Administration (FDA) has announced.
Over the past decade, the pharmaceutical industry has witnessed rapid growth in outsourcing services, driven by various factors including the growth of small molecules, increasing API complexities and the need to optimise costs. Here, Peter DeYoung shares his thoughts on the key trends he expects to see in the contract…
European Pharmaceutical Review explores how plants can be used for large-scale, glycosylated protein bioproduction for the pharma industry.
The dose CMO industry is performing strongly despite challenges of increasingly complex drug production, says a new report.
Loss of manufacturing capability as a result of regulatory non-compliance can have a devastating impact on biopharma or medical device manufacturers. In this article, Jenny Yu shares real-life examples from the industry and highlights the downstream effects of these business interruptions.
The market for containment facilities and containment manufacturing will increase in the future, due to a growing demand for oncology treatments.
Biotechpharma UAB will expand its existing manufacturing facility by adding a new line of bioreactors
It is paramount that manufacturers and their suppliers ensure that the quality of compounded drugs are high, by preventing risks of contamination...
Find out more about PQE Group services from our Vice President and Partner Danilo Neri at last PharmaLab 2018 in Dusseldorf.
